Project: Targeted Treatment of Portal Hypertension in EVH Liver Patients
| Acronym | DeLiver (Reference Number: 10844) |
| Duration | 01/04/2017 |
| Project Topic | DeLiver aims to develop the first targeted treatment for liver patients prone to die from massive bleeding caused by Portal Hypertension (PH). The approach consists of delivering an effective amount of a kinase inhibitor to hepatic stellate cells (HSC) using the proprietary Lx linker and HSC specific nanobodies (called LxL1). DeLiver is a pre-clinical study permitting assessment of LxL1 in a first-in-man (FIM) investigator initiated trial (IIT) for a yet unmet medical condition |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 6 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | LinXis B.V. | Coordinator | Netherlands |
| 2 | Nuvisan | Partner | Germany |
| 3 | Universität Bonn | Partner | Germany |